Journal article
Validating cancer drug targets through chemical genetics
Biochimica et biophysica acta. Reviews on cancer, Vol.1806(2), pp.251-257
12/01/2010
DOI: 10.1016/j.bbcan.2010.08.002
PMCID: PMC3028588
PMID: 20708654
Abstract
Targeted therapies for cancer promise to revolutionize treatment by specifically inactivating pathways needed for the growth of tumor cells. The most prominent example of such therapy is imatinib (Gleevec), which targets the BCR-ABL kinase and provides an effective low-toxicity treatment for chronic myelogenous leukemia. This success has spawned myriad efforts to develop similarly targeted drugs for other cancers. Unfortunately, the high expectations of these efforts have not yet been realized, likely due to the genetic diversity among and within tumors, as well as the complex and largely unpredictable interactions of drug-like compounds with innumerable targets that affect cellular and organismal metabolism. While improvements in sequencing technologies are beginning to address the first problem, solving the second problem requires methods for linking specific features of the cancer genome to their optimally targeted therapies. One approach, referred to as chemical genetics, accomplishes this by genetic control of chemical susceptibility. Chemical genetics is a crucial tool for the rational development of cancer drugs. (C) 2010 Elsevier B.V. All rights reserved.
Details
- Title: Subtitle
- Validating cancer drug targets through chemical genetics
- Creators
- Mark E. Burkard - Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53792 USAPrasad V. Jallepalli - Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10065 USA
- Resource Type
- Journal article
- Publication Details
- Biochimica et biophysica acta. Reviews on cancer, Vol.1806(2), pp.251-257
- Publisher
- Elsevier
- DOI
- 10.1016/j.bbcan.2010.08.002
- PMID
- 20708654
- PMCID
- PMC3028588
- ISSN
- 0304-419X
- eISSN
- 1879-2561
- Number of pages
- 7
- Grant note
- UL1RR025011 / NATIONAL CENTER FOR RESEARCH RESOURCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Research Resources (NCRR) P30CA014520 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) P30 CA014520-31; P30 CA014520-32; P30 CA014520-30; P30 CA014520-34; P30 CA014520-37; P30 CA014520-35; P30 CA014520-33; P30 CA014520; P30 CA014520-38; P30 CA014520-36 / NCI NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) UL1 RR025011-05; UL1 RR025011-03; UL1 RR025011-01; UL1 RR025011; UL1 RR025011-04; UL1 RR025011-02 / NCRR NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Research Resources (NCRR) R01 GM094972-06; R01 GM094972-07; R01 GM094972 / NIGMS NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of General Medical Sciences (NIGMS) R01GM094972 / NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of General Medical Sciences (NIGMS)
- Language
- English
- Date published
- 12/01/2010
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984701258602771
Metrics
4 Record Views